Xin Gao

1.6k total citations · 1 hit paper
55 papers, 1.0k citations indexed

About

Xin Gao is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Xin Gao has authored 55 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Surgery and 13 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Xin Gao's work include Acute Myocardial Infarction Research (7 papers), Atrial Fibrillation Management and Outcomes (6 papers) and Cardiac Arrhythmias and Treatments (5 papers). Xin Gao is often cited by papers focused on Acute Myocardial Infarction Research (7 papers), Atrial Fibrillation Management and Outcomes (6 papers) and Cardiac Arrhythmias and Treatments (5 papers). Xin Gao collaborates with scholars based in China, United States and Australia. Xin Gao's co-authors include Richard Pazdur, Philip J. Marriott, Kirsten B. Goldberg, Ann T. Farrell, Yuan Li Shen, Gideon M. Blumenthal, Xiu‐Wei Yang, Donna Przepiorka, Christopher M. Sheth and Jun Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The American Journal of Cardiology.

In The Last Decade

Xin Gao

48 papers receiving 1.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

2018 252 citations Aviva C. Krauss, Xin Gao et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xin Gao China	15	249	191	163	153	131	55	1.0k
Yoshiyuki Yamamoto Japan	19	398 1.6×	269 1.4×	185 1.1×	82 0.5×	137 1.0×	108	1.1k
Hui Yao China	18	391 1.6×	177 0.9×	145 0.9×	119 0.8×	40 0.3×	53	1.0k
Val R. Adams United States	22	540 2.2×	577 3.0×	272 1.7×	121 0.8×	206 1.6×	62	1.7k
Li Zheng China	21	480 1.9×	156 0.8×	202 1.2×	91 0.6×	32 0.2×	82	1.3k
Xing Jin China	16	278 1.1×	138 0.7×	171 1.0×	75 0.5×	35 0.3×	71	937
John McCaffrey Ireland	15	366 1.5×	393 2.1×	575 3.5×	164 1.1×	34 0.3×	64	1.4k
Elena Magnani Italy	13	406 1.6×	373 2.0×	158 1.0×	230 1.5×	44 0.3×	27	1.2k
Christopher James United States	17	255 1.0×	169 0.9×	83 0.5×	76 0.5×	22 0.2×	49	993
Bernard Royer France	16	275 1.1×	241 1.3×	108 0.7×	59 0.4×	136 1.0×	68	1.2k

Countries citing papers authored by Xin Gao

Since Specialization

Citations

This map shows the geographic impact of Xin Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin Gao more than expected).

Fields of papers citing papers by Xin Gao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin Gao. The network helps show where Xin Gao may publish in the future.

Co-authorship network of co-authors of Xin Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Xin Gao. A scholar is included among the top collaborators of Xin Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin Gao. Xin Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gao, Xin, Yunxin Li, Yanlong Shi, et al.. (2025). The association between different insulin resistance surrogates and all-cause mortality and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease. Cardiovascular Diabetology. 24(1). 200–200. 9 indexed citations

Gao, Xin, Bin Pan, Yawen Liu, et al.. (2025). Elucidating the critical role of gut microbiota in the pathogenesis of bacterial pneumonia: insights from a Mendelian randomization analysis mediated by immune cell. BMC Infectious Diseases. 25(1). 378–378.

Shah, Mirat, Ting-Yu Chen, Gwynn Ison, et al.. (2025). Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Journal of Clinical Oncology. 43(19). 2218–2227. 1 indexed citations

Dilawari, Asma, Hui Zhang, Mirat Shah, et al.. (2025). US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer. Journal of Clinical Oncology. 43(26). 2942–2951. 2 indexed citations

Fallah, Jaleh, Jianjin Xu, Chana Weinstock, et al.. (2024). Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. Journal of Clinical Oncology. 42(14). 1687–1698. 33 indexed citations

Maguire, William F., Daniel Lee, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(10). 2011–2016. 13 indexed citations

Fallah, Jaleh, Jianjin Xu, Hee‐Koung Joeng, et al.. (2024). False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations. JCO Precision Oncology. 8(8). e2400354–e2400354.

Fallah, Jaleh, Brian L. Heiss, Hee‐Koung Joeng, et al.. (2024). FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(22). 5003–5008. 9 indexed citations

Brave, Michael H., William F. Maguire, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(21). 4815–4821. 14 indexed citations

10.

Dilawari, Asma, Christy Osgood, Xin Gao, et al.. (2024). US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations. Journal of Clinical Oncology. 42(34). 4103–4113. 13 indexed citations

11.

Duan, Kaipeng, et al.. (2021). Skeletal muscle depletion and nutrition support affected postoperative complications in patients who underwent pancreatoduodenectomy. European Journal of Clinical Nutrition. 75(8). 1218–1226. 2 indexed citations

12.

Zhou, Bin, Yongjian Zhu, Yingjie Qi, et al.. (2021). Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome. Frontiers in Physiology. 12. 674909–674909. 8 indexed citations

13.

Wedam, Suparna, Lola A. Fashoyin‐Aje, Xin Gao, et al.. (2020). FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer. Clinical Cancer Research. 26(16). 4180–4185. 65 indexed citations

14.

Jen, Emily Y., Xin Gao, Liang Li, et al.. (2019). FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Cancer Research. 26(3). 532–536. 65 indexed citations

15.

Krauss, Aviva C., Xin Gao, Liang Li, et al.. (2018). FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 25(9). 2685–2690. 252 indexed citations breakdown →

16.

Gao, Xin, Lijun Zhang, & Rajeshwari Sridhara. (2017). Exploration of a Novel Intermediate Response Endpoint in Immunotherapy Clinical Studies. Clinical Cancer Research. 24(10). 2262–2267. 4 indexed citations

17.

Ma, Wenfang, Yan Liang, Jun Zhu, et al.. (2015). Comparison of 4 Admission Blood Pressure Indexes for Predicting 30-Day Mortality in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Hypertension. 29(3). 332–339. 18 indexed citations

18.

Gao, Xin, Xiu‐Wei Yang, & Philip J. Marriott. (2013). Evaluation of Coptidis Rhizoma–Euodiae Fructus couple and Zuojin products based on HPLC fingerprint chromatogram and simultaneous determination of main bioactive constituents. Pharmaceutical Biology. 51(11). 1384–1392. 11 indexed citations

19.

Gao, Xin, et al.. (2012). Application of diffusion-weighted MR imaging in the diagnosis of thyroid disease. Zhonghua fangshexian yixue zazhi. 46(6). 500–504. 1 indexed citations

20.

Gao, Xin, Spencer J. Williams, Owen L. Woodman, & Philip J. Marriott. (2010). Comprehensive two-dimensional gas chromatography, retention indices and time-of-flight mass spectra of flavonoids and chalcones. Journal of Chromatography A. 1217(52). 8317–8326. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact